Aleta Biotherapeutics and our Centre for Drug Development have dosed the first patient in a Phase 1/2 clinical trial of Aleta’s CAR T-cell engager.
This pioneering therapy targets patients with relapsed or refractory blood cancer, facing disease progression following CAR T-cell therapy.
Led by Sridhar Chaganti, Chief Investigator at University Hospitals Birmingham NHS Foundation Trust, the trial will assess the safety, dosage, pharmacology, and early efficacy of Aleta’s agent.
This collaboration capitalises on the Centre for Drug Development's expertise in designing clinical trials for novel anti-cancer agents. |